TW491847B - Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one - Google Patents
Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one Download PDFInfo
- Publication number
- TW491847B TW491847B TW086104173A TW86104173A TW491847B TW 491847 B TW491847 B TW 491847B TW 086104173 A TW086104173 A TW 086104173A TW 86104173 A TW86104173 A TW 86104173A TW 491847 B TW491847 B TW 491847B
- Authority
- TW
- Taiwan
- Prior art keywords
- patent application
- scope
- dihydrate
- mesylate
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1675796P | 1996-05-07 | 1996-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW491847B true TW491847B (en) | 2002-06-21 |
Family
ID=21778804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086104173A TW491847B (en) | 1996-05-07 | 1997-04-01 | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
Country Status (40)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| UA57734C2 (uk) | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| NZ551012A (en) * | 2000-06-02 | 2008-04-30 | Pfizer Prod Inc | Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| UY27668A1 (es) * | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| BRPI0410271A (pt) | 2003-05-16 | 2006-05-16 | Pfizer Prod Inc | combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas |
| KR20060015750A (ko) | 2003-06-03 | 2006-02-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법 |
| EP1628973A2 (en) | 2003-10-24 | 2006-03-01 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
| BRPI0510942A (pt) * | 2004-05-11 | 2007-07-17 | Pfizer Prod Inc | combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b |
| CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
| CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
| US7777037B2 (en) * | 2004-10-27 | 2010-08-17 | Dr. Reddy's Laboratories Limited | Ziprasidone process |
| EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| WO2006086787A1 (en) * | 2005-02-11 | 2006-08-17 | Teva Pharmaceutical Industries Ltd. | Process of preparing ziprasidone mesylate |
| CA2593497A1 (en) * | 2005-02-11 | 2006-08-17 | Judith Aronhime | Amorphous ziprasidone mesylate |
| CA2598288A1 (en) * | 2005-03-03 | 2006-09-14 | Elan Pharma International Limited | Nanoparticulate compositions of heterocyclic amide derivatives |
| ITMI20050346A1 (it) | 2005-03-07 | 2006-09-08 | Dipharma Spa | Forma solida di ziprasidone cloridrato |
| CA2500667C (en) | 2005-03-11 | 2013-01-15 | Apotex Pharmachem Inc. | Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions |
| WO2006098834A2 (en) * | 2005-03-14 | 2006-09-21 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of ziprasidone mesylate |
| EP1858892A1 (en) * | 2005-03-14 | 2007-11-28 | Teva Pharmaceutical Industries Ltd | Anhydrous ziprasidone mesylate and a process for its preparation |
| ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
| MX2009011681A (es) * | 2007-05-18 | 2009-11-10 | Scidose Llc | Formulaciones de ziprasidona. |
| WO2009156889A1 (en) * | 2008-06-25 | 2009-12-30 | Pfizer Inc. | Diaryl compounds and uses thereof |
| CN107595771A (zh) * | 2010-10-18 | 2018-01-19 | 大日本住友制药株式会社 | 注射用缓释制剂 |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
| NZ508303A (en) | 1996-05-07 | 2001-07-27 | Pfizer | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone) useful as a dopamine D2 antagonist |
-
1997
- 1997-04-01 TW TW086104173A patent/TW491847B/zh not_active IP Right Cessation
- 1997-04-10 US US09/180,455 patent/US6245765B1/en not_active Expired - Lifetime
- 1997-04-10 IL IL12659197A patent/IL126591A/en not_active IP Right Cessation
- 1997-04-10 PT PT97914520T patent/PT918772E/pt unknown
- 1997-04-10 NZ NZ332218A patent/NZ332218A/en unknown
- 1997-04-10 AT AT97914520T patent/ATE278689T1/de not_active IP Right Cessation
- 1997-04-10 ES ES97914520T patent/ES2229342T3/es not_active Expired - Lifetime
- 1997-04-10 SK SK1508-98A patent/SK282837B6/sk not_active IP Right Cessation
- 1997-04-10 DE DE69731094T patent/DE69731094T2/de not_active Expired - Lifetime
- 1997-04-10 TR TR1998/02240T patent/TR199802240T2/xx unknown
- 1997-04-10 DK DK97914520T patent/DK0918772T3/da active
- 1997-04-10 CN CN97194244A patent/CN1091769C/zh not_active Expired - Fee Related
- 1997-04-10 SI SI9730676T patent/SI0918772T1/xx unknown
- 1997-04-10 KR KR1019980708960A patent/KR100333215B1/ko not_active Expired - Fee Related
- 1997-04-10 BR BR9709889A patent/BR9709889A/pt not_active Application Discontinuation
- 1997-04-10 CA CA002252898A patent/CA2252898C/en not_active Expired - Lifetime
- 1997-04-10 EP EP97914520A patent/EP0918772B1/en not_active Expired - Lifetime
- 1997-04-10 PL PL97329884A patent/PL188330B1/pl unknown
- 1997-04-10 JP JP53967297A patent/JP3494659B2/ja not_active Expired - Lifetime
- 1997-04-10 UA UA98115905A patent/UA46840C2/uk unknown
- 1997-04-10 EA EA199800912A patent/EA001190B1/ru not_active IP Right Cessation
- 1997-04-10 CZ CZ19983493A patent/CZ289215B6/cs not_active IP Right Cessation
- 1997-04-10 AU AU21747/97A patent/AU731267B2/en not_active Ceased
- 1997-04-10 WO PCT/IB1997/000393 patent/WO1997042191A1/en active IP Right Grant
- 1997-04-29 CO CO97022872A patent/CO4940466A1/es unknown
- 1997-04-29 GT GT199700052A patent/GT199700052A/es unknown
- 1997-04-30 AP APAP/P/1997/000976A patent/AP765A/en active
- 1997-05-04 EG EG37997A patent/EG24076A/xx active
- 1997-05-05 AR ARP970101856A patent/AR007004A1/es unknown
- 1997-05-05 ID IDP971492A patent/ID16867A/id unknown
- 1997-05-06 DZ DZ970069A patent/DZ2222A1/fr active
- 1997-05-06 ZA ZA973876A patent/ZA973876B/xx unknown
- 1997-05-06 MY MYPI97001989A patent/MY119997A/en unknown
- 1997-05-06 TN TNTNSN97074A patent/TNSN97074A1/fr unknown
- 1997-05-06 MA MA24595A patent/MA24171A1/fr unknown
- 1997-05-07 HR HR970236A patent/HRP970236B1/xx not_active IP Right Cessation
-
1998
- 1998-10-20 IS IS4874A patent/IS2080B/is unknown
- 1998-10-30 OA OA9800206A patent/OA10909A/fr unknown
- 1998-11-03 BG BG102892A patent/BG63544B1/bg unknown
- 1998-11-06 NO NO19985194A patent/NO312514B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW491847B (en) | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one | |
| JP2742372B2 (ja) | ５−（２−（４−（１，２−ベンゾイソチアゾール−３−イル）−１−ピペラジニル）エチル）−６−クロロ−１，３−ジヒドロ−２ｈ−インドール−２−オン塩酸塩の一水和物 | |
| TW513432B (en) | 2-methyl-thieno-benzodiazepine polymorph and its process for preparation and use | |
| AP838A (en) | Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one. | |
| JP2023175689A (ja) | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 | |
| WO2020221272A1 (zh) | 吲哚类大环衍生物、其制备方法及其在医药上的应用 | |
| JP3199736B2 (ja) | アミノアルキル置換された２−アミノ−５−メルカプトチアジアゾール、その製造及び使用 | |
| CN101203500B (zh) | 取代的芳胺化合物和它们作为5-ht6调节剂的用途 | |
| US6962924B2 (en) | Salt and polymorphs of desloratadine hemifumarate | |
| MXPA98009242A (en) | Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2- |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |